| scholarly article | Q13442814 |
| P2093 | author name string | Chris Fellner | |
| P2860 | cites work | Cancer immunotherapy: moving beyond current vaccines | Q24548229 |
| Improved Endpoints for Cancer Immunotherapy Trials | Q24603112 | ||
| Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma | Q27005902 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? | Q28253687 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| Final version of 2009 AJCC melanoma staging and classification | Q29614803 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma | Q33396455 | ||
| The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases | Q34111899 | ||
| High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. | Q34616628 | ||
| Clinical practice. Dysplastic nevi | Q35600912 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Role of sun exposure in melanoma | Q36471692 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| Temozolomide for the treatment of metastatic melanoma | Q36852256 | ||
| Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies | Q37000638 | ||
| Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment | Q37288227 | ||
| Current systemic therapy for metastatic melanoma | Q37483961 | ||
| Ipilimumab: a novel treatment for metastatic melanoma | Q37866936 | ||
| Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. | Q39711652 | ||
| The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. | Q39852544 | ||
| OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma | Q39866378 | ||
| A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma | Q43293811 | ||
| Hemophilia A induced by ipilimumab | Q45874695 | ||
| Phase I/II study of ipilimumab for patients with metastatic melanoma | Q46087025 | ||
| Ipilimumab. | Q55054369 | ||
| Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'? | Q55167727 | ||
| A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma | Q56898845 | ||
| Treating Cancer by Targeting the Immune System | Q56899478 | ||
| Dysplastic nevi. Markers for increased risk for melanoma | Q69935984 | ||
| Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma | Q71758295 | ||
| Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen | Q74009023 | ||
| Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma | Q74321019 | ||
| Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax | Q78814973 | ||
| Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma | Q79979019 | ||
| Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission | Q82713952 | ||
| P433 | issue | 9 | |
| P921 | main subject | ipilimumab | Q2459042 |
| P304 | page(s) | 503-530 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | P & T: journal for formulary management | Q15767306 |
| P1476 | title | Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. | |
| P478 | volume | 37 |
| Q92377668 | A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade |
| Q39239484 | A review of the importance of immune responses in luminal B breast cancer. |
| Q87640700 | A survey of breakthrough therapy designations |
| Q37210896 | AACR Cancer Progress Report 2015 |
| Q35104530 | Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome |
| Q38837762 | Bending the Cost Curve in Childhood Cancer |
| Q92946963 | Cancer drug development: The missing links |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q47882190 | Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects |
| Q92026257 | Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium |
| Q92317540 | Current state of melanoma diagnosis and treatment |
| Q37437556 | Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis |
| Q26744527 | Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response |
| Q26829997 | Emerging targeted therapies for melanoma treatment (review) |
| Q34524746 | First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma |
| Q38908076 | Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines |
| Q38392912 | Immune biomarkers: the promises and pitfalls of personalized medicine. |
| Q57483931 | Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer |
| Q37393253 | Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab |
| Q45904325 | Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production. |
| Q39627433 | Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication |
| Q51071853 | Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. |
| Q88060558 | Nanoparticle Design Strategies for Effective Cancer Immunotherapy |
| Q28081774 | Overcoming tumor immune evasion with an unique arbovirus |
| Q28067141 | PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses |
| Q28076905 | PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug delivery |
| Q55352057 | Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. |
| Q60652342 | Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study |
| Q52608848 | Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. |
| Q38831830 | Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials |
| Q33946513 | Targeting the PD-1 pathway: a promising future for the treatment of melanoma. |
| Q57148977 | The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers |
| Q36771571 | The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma |
| Q59128386 | The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis |
| Q64256609 | The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer |
| Q33634914 | Treatment patterns in patients with metastatic melanoma: a retrospective analysis |
| Q38730989 | Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors |
| Q27014693 | Update on the challenges and recent advances in cancer immunotherapy |
| Q53641696 | What's fueling the biotech engine-2012 to 2013. |
| Q98613558 | Why natural killer cells in triple negative breast cancer? |